A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.

ABSTRACT:

Importance

Moving to multigene testing for all women with breast cancer (BC) could identify many more mutation carriers who can benefit from precision prevention. However, the cost-effectiveness of this approach remains unaddressed.

Objective

To estimate incremental lifetime effects, costs, and cost-effectiveness of multigene testing of all patients with BC compared with the current practice of genetic testing (BRCA) based on family history (FH) or clinical criteria.

Design, setting, and participants

This cost-effectiveness microsimulation modeling study compared lifetime costs and effects of high-risk BRCA1/BRCA2/PALB2 (multigene) testing of all unselected patients with BC (strategy A) with BRCA1/BRCA2 testing based on FH or clinical criteria (strategy B) in United K

SUBMITTER: Sun L 

PROVIDER: S-EPMC6777250 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature